Celada et al. 38 reported that inhibiting STAT3 expression in T lymphocytes could mediate the release of TGFβ and IL17A, thereby ameliorating fibroblast activation and lung fibrosis. This evidence concerns the gene IL17A and pulmonary fibrosis.